公开(公告)号：US06528273B2

公开(公告)日：2003-03-04

申请号：US09771195

申请日：2001-01-26

申请人： Pamela L. Hawkins

发明人： Pamela L. Hawkins

IPC分类号： C12Q156

CPC分类号： G01N33/86 ,  G01N33/96 ,  G01N2400/40 ,  G01N2496/05

摘要： Coagulation control compositions suitable for use in connection with PT and/or APTT assays are disclosed along with their methods of preparation and methods of use. Preferred coagulation controls comprise plasma and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa. The anticoagulant is preferably a glycosaminoglycan such as heparin, a heparin derivative or a heparin analog. The anticoagulant is preferably combined with (1) an abnormal plasma (e.g. activated plasma or factor-deficient plasma) and/or (2) a primate plasma (e.g. human plasma), and a non-primate mammalian plasma (e.g. bovine plasma). In the latter case, the non-primate mammalian plasma is preferably present in the coagulation control composition in an amount of not more than about 12% by volume, relative to total volume.

摘要翻译： 适用于PT和/或APTT测定结合使用的凝血控制组合以及它们的制备方法和使用方法。 优选的凝血控制包括具有增强抗凝血酶III（ATIII）或肝素辅因子II（HCII）对凝血酶或针对选自因子IXa，Xa和XIa的凝血因子的活性的血浆和抗凝血剂。 抗凝剂优选为糖胺聚糖如肝素，肝素衍生物或肝素类似物。 抗凝剂优选与（1）异常血浆（例如活化血浆或因子缺乏血浆）和/或（2）灵长类动物血浆（例如人血浆）和非灵长类哺乳动物血浆（例如牛血浆）组合。 在后一种情况下，相对于总体积，非灵长类哺乳动物血浆优选以不超过约12体积％的量存在于凝血控制组合物中。

公开(公告)号：US06194394B1

公开(公告)日：2001-02-27

申请号：US09108732

申请日：1998-07-01

申请人： Pamela L. Hawkins

发明人： Pamela L. Hawkins

IPC分类号： A61K31727

CPC分类号： G01N33/86 ,  G01N33/96 ,  G01N2400/40 ,  G01N2496/05

摘要： Coagulation control compositions suitable for use in connection with PT and/or APTT assays are disclosed along with their methods of preparation and methods of use. Preferred coagulation controls comprise plasma and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa. The anticoagulant is preferably a glycosaminoglycan such as heparin, a heparin derivative or a heparin analog. The anticoagulant is preferably combined with (1) an abnormal plasma (e.g. activated plasma or factor-deficient plasma) and/or (2) a primate plasma (e.g. human plasma), and a non-primate mammalian plasma (e.g. bovine plasma). In the latter case, the non-primate mammalian plasma is preferably present in the coagulation control composition in an amount of not more than about 12% by volume, relative to total volume.

摘要翻译： 适用于PT和/或APTT测定结合使用的凝血控制组合以及它们的制备方法和使用方法。 优选的凝血控制包括具有增强抗凝血酶III（ATIII）或肝素辅因子II（HCII）对凝血酶或针对选自因子IXa，Xa和XIa的凝血因子的活性的血浆和抗凝血剂。 抗凝剂优选为糖胺聚糖如肝素，肝素衍生物或肝素类似物。 抗凝剂优选与（1）异常血浆（例如活化血浆或因子缺乏血浆）和/或（2）灵长类动物血浆（例如人血浆）和非灵长类哺乳动物血浆（例如牛血浆）组合。 在后一种情况下，相对于总体积，非灵长类哺乳动物血浆优选以不超过约12体积％的量存在于凝血控制组合物中。

公开(公告)号：US5625036A

公开(公告)日：1997-04-29

申请号：US371052

申请日：1995-01-10

申请人： Pamela L. Hawkins ,  Liliana Tejidor ,  James Maynard ,  Kevin B. Johnson

发明人： Pamela L. Hawkins ,  Liliana Tejidor ,  James Maynard ,  Kevin B. Johnson

IPC分类号： C12Q1/56 ,  A61K9/127 ,  C07K14/745 ,  G01N33/86 ,  C07K4/00

CPC分类号： B82Y5/00 ,  A61K9/127 ,  A61K9/1277 ,  C07K14/745 ,  G01N33/86 ,  G01N2333/745 ,  G01N2405/04

摘要： A prothrombin time reagent is disclosed for use in a prothrombin time test. The reagent utilizes recombinant human tissue factor, phospholipids of a natural or synthetic origin, a buffer composition and calcium ion. Stabilizers and salts may also be utilized in the reagent. In addition, a method for creating lipid micelles containing tissue factor is also disclosed.

摘要翻译： 公开了凝血酶原时间试剂用于凝血酶原时间试验。 该试剂使用重组人组织因子，天然或合成来源的磷脂，缓冲组合物和钙离子。 稳定剂和盐也可用于试剂中。 此外，还公开了一种产生含有组织因子的脂质胶束的方法。

公开(公告)号：US4489162A

公开(公告)日：1984-12-18

申请号：US332781

申请日：1981-12-21

申请人： Pamela L. Hawkins ,  Carole J. Young

发明人： Pamela L. Hawkins ,  Carole J. Young

IPC分类号： G01N33/48 ,  A61K35/18 ,  G01N33/96 ,  C09K3/00

CPC分类号： G01N33/96 ,  G01N2333/765 ,  G01N2400/22 ,  G01N2496/05 ,  Y10T436/101666 ,  Y10T436/105831 ,  Y10T436/107497 ,  Y10T436/108331

摘要： Hematologic control and calibration standards are disclosed which are essentially plasma-free. These controls are prepared by the suspension of red blood cells in an appropriate buffer containing a stabilization effective amount of disaccharides, and other optional ingredients. Control and calibration standards prepared in the foregoing manner are suitable in the control and calibration of hematology analyzers for the following parameters: white cell count, red cell count, hemoglobin, hematocrit and the common derived parameters (i.e., mean cell volume, mean cell hemoglobin and mean cell hemoglobin concentration). The addition of platelets to the foregoing suspensions is also contemplated to provide a control for platelet parameters.

摘要翻译： 公开了基本上无血浆的血液控制和校准标准。 这些对照是通过将红细胞悬浮于含有稳定有效量的二糖和其它任选成分的合适的缓冲液中来制备的。 以上述方法制备的控制和校准标准适用于以下参数的血液分析仪的控制和校准：白细胞计数，红细胞计数，血红蛋白，血细胞比容和常用衍生参数（即平均细胞体积，平均细胞血红蛋白 和平均细胞血红蛋白浓度）。 还预期将血小板加入到前述悬浮液中以提供血小板参数的控制。